A RESOLUTION encouraging the Kentucky Department for Public Health, in conjunction with the Kentucky Office of Drug Control Policy, to issue a public statement to increase awareness in the Commonwealth on the potential harm of consuming 7-hydroxymitragynine products.
House Resolution 88 is a nonbinding resolution that urges the Kentucky Department for Public Health, working with the Kentucky Office of Drug Control Policy, to issue a public statement warning Kentuckians about the potential harms of consuming 7-hydroxymitragynine products. The resolution frames 7-hydroxymitragynine as a compound found in kratom, noting that it acts on opioid receptors and may produce opioid-like effects such as sedation, nausea, vomiting, dependence, withdrawal, and respiratory depression.
The resolution also states that some products marketed as kratom may contain artificially increased or synthetic levels of 7-hydroxymitragynine, and it cites research and FDA-related concerns suggesting the substance can be highly potent and may contribute to use of other opioids. It directs the House Clerk to transmit the resolution to the Department for Public Health, the Office of Drug Control Policy, and the Governor, but it does not itself change criminal, health, or consumer protection law.
Because HR88 is a resolution rather than a bill, it does not amend Kentucky statutes or create enforceable regulatory requirements. Its practical effect would be advisory and public-facing: it encourages state health and drug policy agencies to warn the public about 7-hydroxymitragynine and related kratom products, potentially influencing public health messaging, consumer awareness, and future policy discussions about kratom, synthetic alkaloids, and opioid-like substances.
The available text suggests a strongly cautionary and public-health-oriented sentiment. The resolution is framed around risks, addiction potential, and opioid-like harms, indicating support for warning the public rather than promoting access or regulation leniency. No committee transcript or vote record is provided, so there is no direct evidence of opposition or debate in the supplied materials.
The main point of contention implied by the resolution is the safety and marketing of kratom-related products, especially those that may contain concentrated or synthetic 7-hydroxymitragynine. Supporters would likely emphasize overdose risk, dependence, and misleading labeling, while potential critics could argue that the resolution may overstate harms, conflate kratom with isolated compounds, or contribute to stigma around products used by some consumers for pain relief or self-treatment. No recorded committee discussion or vote history is available here to identify specific legislators or stakeholder positions.